Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa

Pharmaceutical Research

Volumn 18, Issue 6, 2001, Pages 788-793

  Lamprecht, A ^a   Schafer U ^a   Lehr, C M ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Drug targeting; Inflammatory bowel disease; Microspheres; Nanospheres; Ulcerative colitis

Indexed keywords

NANOPARTICLE; POLYSTYRENE; TRINITROBENZENESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON MUCOSA; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; NONHUMAN; PARTICLE SIZE; PARTICULATE MATTER; PRIORITY JOURNAL; RAT; SPECTROFLUOROMETRY; ULCERATIVE COLITIS;

ADHESIVES; ANIMALS; CAPSULES; COLITIS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; INTESTINAL MUCOSA; PARTICLE SIZE; RATS; RATS, INBRED LEW;

EID: 0034872426     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011032328064     Document Type: Article

References (30)

1. Glucocorticoiddextran conjugates as potential prodrugs colon-specific delivery: Hydrolysis in rat gastrointestinal tract contents
2. Colonic delivery of dexamethasone from a prodrug accelerates healing of colitis in rats without adrenal suppression
3. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid
4. Medical therapy of ulcerative colitis
5. Colonic drug delivery
6. Colonic drug targeting
7. Colon-specific delivery of budenoside with azopolymer-coated pellets: Therapeutic effects of budenoside with a novel dosage form against 2,4,6-trinitrobenzene sulphonic acid-induced colitis in rats
8. Gastrointestinal transit of small tablets in patients with ulcerative colitis
9. The transit rate of different-sized model dosage forms through the human colon and the effects of a lactulose-induced catharsis
10. Design of a new multiparticulate system for potential site specific and controlled drug delivery to the colonic region
11. Development of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: A new therapeutic strategy
12. Macrophage heterogeneity in normal colonic mucosa and in inflammatory bowel disease
13. Dentritic cells and scavanger macrophage in chronic inflammatory bowel disease
14. Persistent clonal expansion of peripheral blood CD4+ lymphocytes in chronic inflammatory bowel disease
15. Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres
16. Intracellular visualization of ampicillin-loaded nanoparticles in peritoneal macrophages infected in vitro with Salmonella typhimurium
17. Disruption of intestinal barrier function associated with experimental colitis: Possible role of mast cells
18. The 21-aminosteroid tirilazad mesylate can ameliorate inflammatory bowel disease in rats
19. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity
20. A comparative analysis of two models of colitis in rats
21. Hapten-induced model of chronic inflammation and ulceration in the rat colon
22. Gastrointestinal uptake of biodegradable microparticles: Effects of particle size
23. The uptake and translocation of latex nanospheres and microspheres after oral administration to rats
24. Nanoparticle uptake by the ratgastrointestinal mucosa: Quantitation and particle size dependency
25. Mucoadhesion of polystyrene nanoparticles having surface hydrophilic polymeric chains in the gastrointestinal tract
26. Migration of adhesive and nonadhesive particles in the rat intestine under altered mucus secretion conditions
27. Phagocytosis of polymer microspheres by macrophages
28. Experimental models of inflammatory bowel disease
29. Uptake of nanoparticles by rat glomerular mesangial cells in vivo and in vitro
30. Mechanisms of action of sulcrafate